Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Charles Beasley

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Double-Blind Method

Disorders

Concepts & Ideas

Devices

Placebos

Activities & Behaviors

Suicide

Phenomena

Recurrence

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
15
Tollefson, Gary
11
Tran, Pierre
9
Amsterdam, Jay
9
Quitkin, Frederic
8
Reimherr, Frederick
6
Dellva, MA
5
Hamilton, Susan
5
Rosenbaum, Jerrold
4
Sanger, Todd
4
Michelson, David
4
Fawcett, Jan
4
Taylor, Cindy
3
Zajecka, John
3
Emmick, Jeffrey
3
Dossenbach, Martin

Sign-in to see all Coauthors

Publications

TOP 3
Beasley Charles M; Ball Susan G; Nilsson Mary E; Polzer John; Tauscher-Wisniewski Sitra; Plewes John; Acharya Nayan
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.
Tauscher-Wisniewski Sitra; Disch Damon; Plewes John; Ball Susan; Beasley Charles M
Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder.
Beasley Charles M; Stauffer Virginia L; Liu-Seifert Hong; Taylor Cindy C; Dunayevich Eduardo; Davis John M
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Charles Beasley (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Beasley Charles M; Ball Susan G; Nilsson Mary E; Polzer John; Tauscher-Wisniewski Sitra; Plewes John; Acharya Nayan
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.
Journal of clinical psychopharmacology 2007;27(6):682-6.
2007: Tauscher-Wisniewski Sitra; Disch Damon; Plewes John; Ball Susan; Beasley Charles M
Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder.
Psychological medicine 2007;37(11):1585-93.
2007: Beasley Charles M; Stauffer Virginia L; Liu-Seifert Hong; Taylor Cindy C; Dunayevich Eduardo; Davis John M
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.
Journal of clinical psychopharmacology 2007;27(3):252-8.
2007: Cusin Cristina; Fava Maurizio; Amsterdam Jay D; Quitkin Frederic M; Reimherr Frederick W; Beasley Charles M; Rosenbaum Jerrold F; Perlis Roy H
Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications.
The Journal of clinical psychiatry 2007;68(1):52-7.
2007: Perlis Roy H; Beasley Charles M; Wines James D; Tamura Roy N; Cusin Cristina; Shear Deborah; Amsterdam Jay; Quitkin Frederick; Strong Robert E; Rosenbaum Jerrold F; Fava Maurizio
Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.
Psychotherapy and psychosomatics 2007;76(1):40-6.
2006: Crumb William J; Ekins Sean; Sarazan R Dustan; Wikel James H; Wrighton Steven A; Carlson Christopher; Beasley Charles M
Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.
Pharmaceutical research 2006;23(6):1133-43.
2006: Beasley Charles M; Sutton Virginia K; Taylor Cindy C; Sethuraman Gopalan; Dossenbach Martin; Naber Dieter
Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
Journal of clinical psychopharmacology 2006;26(1):40-4.
2005: Carrier Serge; Brock Gerald B; Pommerville Peter J; Shin Janey; Anglin Greg; Whitaker Steven; Beasley Charles M
Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial.
The journal of sexual medicine 2005;2(5):685-98.
2005: Beasley Charles M; Mitchell Malcolm I; Dmitrienko Alex A; Emmick Jeffrey T; Shen Wei; Costigan Timothy M; Bedding Alun W; Turik Michael A; Bakhtyari Arash; Warner Margaret R; Ruskin Jeremy N; Cantilena Louis R; Kloner Robert A
The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval.
Journal of the American College of Cardiology 2005;46(4):678-87.
2005: Young Jay M; Feldman Robert A; Auerbach Stephen M; Kaufman Joel M; Garcia Carmen S; Shen Wei; Murphy Aileen M; Beasley Charles M; Hague Jayne A; Ahuja Sanjeev
Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.
Journal of andrology 2005;26(3):310-8.
2004: Dustan Sarazan R; Crumb William J; Beasley Charles M; Emmick Jeffrey T; Ferguson Kenneth M; Strnat Christine A; Sausen Peter J
Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
European journal of pharmacology 2004;502(3):163-7.
2004: von Keitz Alexander; Rajfer Jacob; Segal Scott; Murphy Aileen; Denne Jonathan; Costigan Timothy; Lockhart Daniel; Beasley Charles M; Emmick Jeffrey T
A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.
European urology 2004;45(4):499-507; discussion 507-9.
2003: Beasley Charles M; Sutton Virginia K; Hamilton Susan H; Walker Daniel J; Dossenbach Martin; Taylor Cindy C; Alaka Karla J; Bykowski Deborah; Tollefson Gary D;
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
Journal of clinical psychopharmacology 2003;23(6):582-94.
2003: Hellstrom Wayne J G; Overstreet James W; Yu Albert; Saikali Khalil; Shen Wei; Beasley Charles M; Watkins Vish S
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.
The Journal of urology 2003;170(3):887-91.
2003: Carlson Christopher D; Cavazzoni Patrizia A; Berg Paul H; Wei Hank; Beasley Charles M; Kane John M
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
The Journal of clinical psychiatry 2003;64(8):898-906.
2003: Lindborg Stacy R; Beasley Charles M; Alaka Karla; Taylor Cindy C
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.
Psychiatry research 2003;119(1-2):113-23.
2003: Inada Toshiya; Beasley Charles M; Tanaka Yoko; Walker Daniel J
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
International clinical psychopharmacology 2003;18(1):39-48.
2002: Sowell Margaret O; Mukhopadhyay Nitai; Cavazzoni Patrizia; Shankar Sudha; Steinberg Helmut O; Breier Alan; Beasley Charles M; Dananberg Jamie
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.
The Journal of clinical endocrinology and metabolism 2002;87(6):2918-23.
2002: Brunswick David J; Amsterdam Jay D; Fawcett Jan; Quitkin Frederic M; Reimherr Frederick W; Rosenbaum Jerrold F; Beasley Charles M
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment.
Journal of affective disorders 2002;68(2-3):243-9.
2002: Meehan Karena M; Wang Huei; David Stacy R; Nisivoccia Jennifer R; Jones Barry; Beasley Charles M; Feldman Peter D; Mintzer Jacobo E; Beckett Louise M; Breier Alan
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;26(4):494-504.
2001: Brunswick D J; Amsterdam J D; Fawcett J; Quitkin F M; Reimherr F W; Rosenbaum J F; Beasley C M
Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.
Journal of clinical psychopharmacology 2001;21(6):616-8.
2001: Kennedy J S; Bymaster F P; Schuh L; Calligaro D O; Nomikos G; Felder C C; Bernauer M; Kinon B J; Baker R W; Hay D; Roth H J; Dossenbach M; Kaiser C; Beasley C M; Holcombe J H; Effron M B; Breier A
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.
International journal of geriatric psychiatry 2001;16 Suppl 1():S33-61.
2001: Czekalla J; Beasley C M; Dellva M A; Berg P H; Grundy S
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
The Journal of clinical psychiatry 2001;62(3):191-8.
2001: Czekalla J; Kollack-Walker S; Beasley C M
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
The Journal of clinical psychiatry 2001;62 Suppl 2():35-40.
2000: Beasley C M; Koke S C; Nilsson M E; Gonzales J S
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
Clinical therapeutics 2000;22(11):1319-30.
2000: Beasley C M; Nilsson M E; Koke S C; Gonzales J S
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
The Journal of clinical psychiatry 2000;61(10):722-8.
2000: McGrath P J; Stewart J W; Petkova E; Quitkin F M; Amsterdam J D; Fawcett J; Reimherr F W; Rosenbaum J F; Beasley C M
Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression.
The Journal of clinical psychiatry 2000;61(7):518-24.
1999: Callaghan J T; Bergstrom R F; Ptak L R; Beasley C M
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Clinical pharmacokinetics 1999;37(3):177-93.
1999: Revicki D A; Genduso L A; Hamilton S H; Ganoczy D; Beasley C M
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1999;8(5):417-26.
1999: Michelson D; Amsterdam J D; Quitkin F M; Reimherr F W; Rosenbaum J F; Zajecka J; Sundell K L; Kim Y; Beasley C M
Changes in weight during a 1-year trial of fluoxetine.
The American journal of psychiatry 1999;156(8):1170-6.
1999: Zajecka J; Amsterdam J D; Quitkin F M; Reimherr F W; Rosenbaum J F; Tamura R N; Sundell K L; Michelson D; Beasley C M
Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
The Journal of clinical psychiatry 1999;60(6):389-94.
1999: Beasley C M
Response to letter of Professor Tim Lambert.
The Australian and New Zealand journal of psychiatry 1999;33(1):121-2.
1999: Beasley C M; Dellva M A; Tamura R N; Morgenstern H; Glazer W M; Ferguson K; Tollefson G D
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
The British journal of psychiatry : the journal of mental science 1999;174():23-30.
1999: Tran P V; Tollefson G D; Sanger T M; Lu Y; Berg P H; Beasley C M
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
The British journal of psychiatry : the journal of mental science 1999;174():15-22.
1998: Reimherr F W; Amsterdam J D; Quitkin F M; Rosenbaum J F; Fava M; Zajecka J; Beasley C M; Michelson D; Roback P; Sundell K
Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.
The American journal of psychiatry 1998;155(9):1247-53.
1998: Tran P V; Dellva M A; Tollefson G D; Wentley A L; Beasley C M
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
The British journal of psychiatry : the journal of mental science 1998;172():499-505.
1998: Tollefson G D; Sanger T M; Beasley C M; Tran P V
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Biological psychiatry 1998;43(11):803-10.
1998: Hamilton S H; Revicki D A; Genduso L A; Beasley C M
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;18(1):41-9.
1997: Dellva M A; Tran P; Tollefson G D; Wentley A L; Beasley C M
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Psychiatric services (Washington, D.C.) 1997;48(12):1571-7.
1997: Goldstein D J; Hamilton S H; Masica D N; Beasley C M
Fluoxetine in medically stable, depressed geriatric patients: effects on weight.
Journal of clinical psychopharmacology 1997;17(5):365-9.
1997: Tollefson G D; Beasley C M; Tamura R N; Tran P V; Potvin J H
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
The American journal of psychiatry 1997;154(9):1248-54.
1997: Crawford A M; Beasley C M; Tollefson G D
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Schizophrenia research 1997;26(1):41-54.
1997: Amsterdam J D; Fawcett J; Quitkin F M; Reimherr F W; Rosenbaum J F; Michelson D; Hornig-Rohan M; Beasley C M
Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.
The American journal of psychiatry 1997;154(7):963-9.
1997: Tran P V; Dellva M A; Tollefson G D; Beasley C M; Potvin J H; Kiesler G M
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
The Journal of clinical psychiatry 1997;58(5):205-11.
1997: Beasley C M; Hamilton S H; Crawford A M; Dellva M A; Tollefson G D; Tran P V; Blin O; Beuzen J N
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1997;7(2):125-37.
1997: Tollefson G D; Beasley C M; Tran P V; Street J S; Krueger J A; Tamura R N; Graffeo K A; Thieme M E
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
The American journal of psychiatry 1997;154(4):457-65.
1997: Blumenfield M; Levy N B; Spinowitz B; Charytan C; Beasley C M; Dubey A K; Solomon R J; Todd R; Goodman A; Bergstrom R F
Fluoxetine in depressed patients on dialysis.
International journal of psychiatry in medicine 1997;27(1):71-80.
1997: Beasley C M; Tollefson G D; Tran P V
Safety of olanzapine.
The Journal of clinical psychiatry 1997;58 Suppl 10():13-7.
1997: Beasley C M; Tollefson G D; Tran P V
Efficacy of olanzapine: an overview of pivotal clinical trials.
The Journal of clinical psychiatry 1997;58 Suppl 10():7-12.
1996: Beasley C M; Sanger T; Satterlee W; Tollefson G; Tran P; Hamilton S
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.
Psychopharmacology 1996;124(1-2):159-67.
1996: Beasley C M; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(2):111-23.
1996: Levy N B; Blumenfield M; Beasley C M; Dubey A K; Solomon R J; Todd R; Goodman A; Bergstrom R R
Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function.
General hospital psychiatry 1996;18(1):8-13.
1994: Tollefson G D; Rampey A H; Beasley C M; Enas G G; Potvin J H
Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
Journal of clinical psychopharmacology 1994;14(3):163-9.
1994: Beasley C M
Fluoxetine-dopaminergic interaction data.
The Journal of clinical psychiatry 1994;55(2):77-9.
1993: Tollefson G D; Fawcett J; Winokur G; Beasley C M; Potvin J H; Faries D E; Rampey A H; Sayler M E
Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 1993;5(4):209-24.
1993: Beasley C M; Masica D N; Heiligenstein J H; Wheadon D E; Zerbe R L
Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.
Journal of clinical psychopharmacology 1993;13(5):312-20.
1993: Beasley C M; Holman S L; Potvin J H
Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 1993;5(3):199-207.
1993: Goldstein D J; Rampey A H; Potvin J H; Masica D N; Beasley C M
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
The Journal of clinical psychiatry 1993;54(8):309-16.
1993: Heiligenstein J H; Beasley C M; Potvin J H
Fluoxetine not associated with increased aggression in controlled clinical trials.
International clinical psychopharmacology 1993;8(4):277-80.
1993: Beasley C M; Potvin J H
Fluoxetine: activating and sedating effects.
International clinical psychopharmacology 1993;8(4):271-5.
1993: Bergstrom R F; Beasley C M; Levy N B; Blumenfield M; Lemberger L
The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine.
International clinical psychopharmacology 1993;8(4):261-6.
1993: Beasley C M; Sayler M E; Potvin J H
Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial.
International clinical psychopharmacology 1993;8(3):143-9.
1992: Beasley C M; Sayler M E; Weiss A M; Potvin J H
Fluoxetine: activating and sedating effects at multiple fixed doses.
Journal of clinical psychopharmacology 1992;12(5):328-33.
1992: Masica D N; Kotsanos J G; Beasley C M; Potvin J H
Trend in suicide rates since fluoxetine introduction.
American journal of public health 1992;82(9):1295.
1992: Wheadon D E; Rampey A H; Thompson V L; Potvin J H; Masica D N; Beasley C M
Lack of association between fluoxetine and suicidality in bulimia nervosa.
The Journal of clinical psychiatry 1992;53(7):235-41.
1992: Beasley C M; Potvin J H; Masica D N; Wheadon D E; Dornseif B E; Genduso L A
Fluoxetine: no association with suicidality in obsessive-compulsive disorder.
Journal of affective disorders 1992;24(1):1-10.
1992: Beasley C M; Masica D N; Potvin J H
Fluoxetine: a review of receptor and functional effects and their clinical implications.
Psychopharmacology 1992;107(1):1-10.
1991: Beasley C M
Fluoxetine and suicide.
BMJ (Clinical research ed.) 1991;303(6811):1200.
1991: Fuller R W; Beasley C M
Fluoxetine mechanism of action.
Journal of the American Academy of Child and Adolescent Psychiatry 1991;30(5):849-50.
1991: Beasley C M; Dornseif B E; Bosomworth J C; Sayler M E; Rampey A H; Heiligenstein J H; Thompson V L; Murphy D J; Masica D N
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
BMJ (Clinical research ed.) 1991;303(6804):685-92.
1991: Beasley C M; Dornseif B E; Pultz J A; Bosomworth J C; Sayler M E
Fluoxetine versus trazodone: efficacy and activating-sedating effects.
The Journal of clinical psychiatry 1991;52(7):294-9.
1991: Beasley C M; Sayler M E; Bosomworth J C; Wernicke J F
High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression.
Journal of clinical psychopharmacology 1991;11(3):166-74.
1991: Usher R W; Beasley C M; Bosomworth J C
Efficacy and safety of morning versus evening fluoxetine administration.
The Journal of clinical psychiatry 1991;52(3):134-6.
1990: Beasley C M; Sayler M E; Cunningham G E; Weiss A M; Masica D N
Fluoxetine in tricyclic refractory major depressive disorder.
Journal of affective disorders 1990;20(3):193-200.
1990: McCombs J S; Nichol M B; Stimmel G L; Sclar D A; Beasley C M; Gross L S
The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population.
The Journal of clinical psychiatry 1990;51 Suppl():60-9; discussion 70-1.
1990: Beasley C M; Bosomworth J C; Wernicke J F
Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression.
Psychopharmacology bulletin 1990;26(1):18-24.
1988: Beasley C M; Magnusson M; Garver D L
TSH response to TRH and haloperidol response latency in psychoses.
Biological psychiatry 1988;24(4):423-31.

Sign-in to see more